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Abstract
Background: Adipokines and inflammation may provide a mechanistic link between obesity and postmenopausal breast
cancer, yet epidemiologic data on their associations with breast cancer risk are limited.
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Methods: In a case-cohort analysis nested within the Women’s Health Initiative Observational Study, a prospective cohort
of postmenopausal women, baseline plasma samples from 875 incident breast cancer case patients and 839 subcohort
participants were tested for levels of seven adipokines, namely leptin, adiponectin, resistin, interleukin-6, tumor necrosis
factor-α, hepatocyte growth factor, and plasminogen activator inhibitor-1, and for C-reactive protein (CRP), an inflammatory
marker. Data were analyzed by multivariable Cox modeling that included established breast cancer risk factors and
previously measured estradiol and insulin levels. All statistical tests were two-sided.
Results: The association between plasma CRP levels and breast cancer risk was dependent on hormone therapy (HT) use at
baseline (Pinteraction = .003). In a model that controlled for multiple breast cancer risk factors including body mass index (BMI),
estradiol, and insulin, CRP level was positively associated with breast cancer risk among HT nonusers (hazard ratio for high
vs low CRP levels = 1.67, 95% confidence interval = 1.04 to 2.68, Ptrend = .029). None of the other adipokines were statistically
significantly associated with breast cancer risk. Following inclusion of CRP, insulin, and estradiol in a multivariable model,
the association of BMI with breast cancer was attenuated by 115%.
Conclusion: These data indicate that CRP is a risk factor for postmenopausal breast cancer among HT nonusers.
Inflammatory mediators, together with insulin and estrogen, may play a role in the obesity–breast cancer relation.

Obesity is an established risk factor for breast cancer in postmenopausal women (1,2); however, the biologic mechanisms
underlying this relationship are not fully understood. In postmenopausal women, adiposity is associated with increased
levels of estrogen and insulin, and both experimental and
observational evidence support a role for these factors in breast

tumorigenesis (3,4). Nonetheless, additional factors that are
associated with obesity may also play a role in breast cancer
development (5). Adipose tissue is a highly active endocrine and
metabolic organ that secretes a variety of cytokines and hormones, termed adipokines. In the obese, adipokine levels may
be abnormal, leading to the promotion of pathways implicated
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Methods
Study Population
Women’s Health Initiative (WHI-OS)
This study was conducted among women enrolled in the
WHI-OS, a prospective cohort of 93 676 postmenopausal women
age 50 to 79 years who were recruited through 40 clinical centers across the United States between 1993 and 1998 (23). At
enrollment, WHI-OS participants provided written informed
consent and completed questionnaires regarding demographic
and behavioral factors, medical history, and use of medications
(including hormone therapy [HT]). Each woman underwent
a physical examination that included waist, hip, height, and
weight measurements and provided a blood sample following
an overnight fast of at least eight hours; the blood samples were
processed within two hours of collection and stored at -80°C (24).
Cancer outcomes (including breast cancer) were initially ascertained through annual self-administered questionnaires; breast

cancer status and the detailed diagnosis were subsequently
formally determined through centralized review of medical
records. Breast cancer case patients were coded according to the
National Cancer Institute’s Surveillance, Epidemiology, and End
Results program guidelines (25,26). As of June 2004, when the
participants included in this case-cohort study were selected,
1.6% of the WHI-OS women had been lost to follow-up, and 4.7%
were deceased.
Study Participants
WHI-OS participants were eligible for this case-cohort study if
they had more than one year of follow-up and had no history
of breast cancer before the end of year one. From these eligible
participants, case patients were women who had a subsequent
incident diagnosis of breast cancer after the first year of followup. We randomly selected 903 of the approximately 1800 eligible
case participants available at the time this study was initiated.
The comparison group was a subcohort of 892 participants who
were randomly chosen from the eligible WHI-OS participants
regardless of their subsequent breast cancer status. As such, 18
subcohort participants were also included in the case group. We
also excluded participants who were using diabetes treatments
at baseline (n = 28 case patients and 53 subcohort participants)
because these treatments can have an impact on levels of the
factors measured in our study. Therefore, the final analytic data
set included 875 incident breast cancer case patients and 839
subcohort participants.

Laboratory Methods
EDTA plasma levels of adiponectin, PAI-1, and resistin were measured using Milliplex Human Adipokine Panel-A (EMD Millipore,
Billerica, MA), and their interassay coefficients of variation (CV)
were 13%, 12%, and 12%, respectively. Leptin, HGF, and TNF-α
levels were assayed with Milliplex Human Adipokine Panel-B
(interassay CVs = 9%, 12% and 13%, respectively). IL-6 levels were
measured using an ultrasensitive solid-phase sandwich ELISA
(R&D Systems, Minneapolis, MN; interassay CV = 10%), while
CRP was assessed with latex-enhanced immunonephelometry
on the Behring nephelometer II analyzer (Behring Diagnostics,
San Jose, CA; interassay CV = 4%). Assay methods for insulin and
estradiol have been described previously (3). The proportion of
participants with measures below the limit of detection (LOD)
was very low and ranged from 0% for leptin to 2.3% for TNF-α.
For samples with an undetectable level below the assay LOD,
the values were imputed using 0.5*LOD. The three-year intraclass correlation coefficients (ICC) for the seven adipokines and
for insulin and estradiol have been reported previously and
ranged from 0.39 for TNF-α to 0.95 for resistin (27–29). The fiveyear ICC of CRP was reported to be 0.83 (30).

Statistical Analyses
Differences in the distributions of baseline characteristics
between case patients and the subcohort members without
breast cancer were evaluated using the Wilcoxon rank sum
test (for continuous data) or the chi-square test (for categorical
data). To examine the associations between the serologic factors and risk of breast cancer, we estimated hazard ratios (HRs)
and 95% confidence intervals (CIs) using Cox proportional hazard regression models that employed the Self-Prentice method
for computing robust standard error estimates to account for
the case-cohort design (31). The proportionality of the data
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in breast tumorigenesis. For example, inflammatory cytokines
such as interleukin-6 (IL-6) and tumor necrosis factor (TNF)-α
are upregulated in obesity and have been demonstrated to promote breast tumor initiation and progression (6,7). Adipokines
and associated inflammatory mediators may, therefore, provide an important mechanistic link between obesity and breast
cancer.
Epidemiologic data on the association of adipokines
and inflammatory factors with breast cancer are limited.
Adiponectin, a hormone that improves insulin resistance and
has been shown to have anti-mitogenic activity in vitro, was
inversely associated with breast cancer incidence in some prior
prospective investigations (8,9) but not in other studies (10,11),
though three recent meta-analyses that included both prospective cohort and case-control studies reported an inverse
relationship between adiponectin levels and breast cancer
risk (12–14). Data on the association of other adipokines with
breast cancer risk, such as leptin, plasminogen activator inhibitor (PAI)–1, and resistin are also mixed (9–11). C-reactive protein
(CRP), a sensitive yet nonspecific marker of the inflammatory
response, has also generally not been found to be statistically
significantly associated with breast cancer risk (15–21). However,
most studies evaluated a relatively small number of breast cancer case patients and most included both pre- and postmenopausal breast cancers, tumors that are known to differ in their
association with body habitus.
To advance knowledge on the role of adipokines and inflammation in breast cancer development, we conducted a casecohort study within the Women’s Health Initiative Observational
Study (WHI-OS) to comprehensively evaluate the associations of
postmenopausal breast cancer with circulating levels of CRP and
seven adipokines, namely IL-6, TNF-α, adiponectin, leptin, resistin, hepatocyte growth factor (HGF), and PAI-1. This study builds
upon previous findings on the role of insulin and estrogen in
breast cancer development obtained from WHI-OS participants
(3,22) by comprehensively assessing key adipokines and inflammatory mediators in a well-characterized study population of
postmenopausal women. With existing measurements of other
obesity-related factors, this study had the unique opportunity to
assess whether adipokines, inflammatory factors, estradiol, and
insulin could be part of the mechanisms linking obesity with
breast cancer risk in postmenopausal women. Evaluating these
obesity-related pathways simultaneously in one study has, to
our knowledge, not been done previously.
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was verified by graphical inspection and by Schoenfeld residuals. All serologic variables were expressed as quartiles with
cutpoints based on the distributions of data in the subcohort.
Trend tests were performed using Wald tests associated with
fitting the quartile categories as continuous variables in the
regression model.
In the primary analysis, we computed two models for each
analyte: a base model that included age (50–54 [referent], 55–64,
65–74, or 75+ years) and race/ethnicity (white [referent], black,
others) and an extended multivariable model that additionally
included other breast cancer risk factors that were significantly
associated with breast cancer risk in multivariable modeling in
the study population, namely physical activity (metabolic equivalent tasks [METs], defined as the caloric need per kilogram of
body weight per hour of activity divided by the caloric need per
kilogram of body weight per hour at rest) and categorized as
quartiles (<3.75, 3.75–9.99, 10–19.99, ≥20); body mass index (BMI;
<25.0 [referent], 25.0–29.9, ≥30.0 kg/m2); alcohol consumption,
assessed as the number of servings per week (none [referent],
<1.57, ≥1.57); family history of breast cancer in first-degree relatives (yes/no); parity (0 [referent], ≥1 live births); age at first child’s
birth (<25 [referent], ≥25 years); years of menstrual cycling (≤33,
34–38, ≥39); history of benign breast disease (yes/no), estrogen
status (serum estradiol among women who were not using HT
[<8, ≥8 pg/mL] or women using HT at baseline). In another multivariable model, insulin was included as an additional covariate
(quartiles of insulin, ≤3.3 [referent], 3.4–5.3, 5.4–8.5, or ≥8.6 μIU/
mL), thus, controlling for both insulin and estradiol, in addition
to other covariates. Variables that were not significantly associated with breast cancer risk in multivariable analysis in our
study population, including smoking status, use of nonsteroidal
anti-inflammatory drugs (NSAIDs), oral contraceptive use and
educational history, were not included as covariates in the final
multivariable model.
We explored whether the associations of breast cancer risk
with the adipokines and inflammatory markers differed by
baseline HT use (current user [n = 836] or nonuser [n = 859]) and
BMI (<30 [n = 1279] or ≥30 [n = 417] kg/m2) because both HT use
and BMI are known to have substantial effects on adipokine and
inflammatory factor levels and are statistically significant risk
factors for postmenopausal breast cancer. These stratified analyses were conducted by introducing interaction terms into multivariable models that also included the main effect variables. In
addition, we conducted separate analyses for estrogen receptor
(ER)–positive and ER-negative breast cancers.
All tests of statistical significance were two-sided, and P values under .05 were considered statistically significant.

Results
The baseline characteristics of the incident breast cancer case
patients and subcohort are presented in Table 1. In univariable
analyses, compared with women in the subcohort, case patients
were older, had a later onset of menopause, gave birth to their
first child at a later age, had greater alcohol consumption, had a
higher frequency of NSAID use, and more often reported being a
former smoker. Case patients were also more likely than women
in the subcohort to have a first-degree relative with breast cancer, to be using HT, and to have a history of benign breast disease
(Table 1).
Correlations of the adipokines with each other and with
insulin, estradiol, and BMI among the subcohort members
have been reported previously (32,33), and these correlations
among participants not using HT at baseline are presented in

Supplementary Table 1 (available online). In brief, among HT
nonusers in the representative subcohort, BMI had a moderate
correlation with leptin (r = 0.70), insulin (r = 0.59), CRP (r = 0.50),
and IL-6 (r = 0.41). Among the serologic factors, a moderate,
inverse correlation was found between insulin and adiponectin
(r = -0.46), while moderate, positive correlations were observed
between insulin and leptin (r = 0.58), CRP and IL-6 (r = 0.59), CRP
and insulin (r = 0.37), and CRP and leptin (r = 0.43).

Associations of Adipokines With Breast Cancer
Overall, we did not observe any statistically significant associations between leptin, resistin, IL-6, TNF-α, and HGF with breast
cancer risk in age- and ethnicity-adjusted or multivariable models that included established breast cancer risk factors (Table 2).
There was a suggestive inverse association between adiponectin and breast cancer with the hazard ratios for the third and
fourth adiponectin quartiles, compared with the first quartile, of
borderline statistical significance (Ptrend = .078). When combined
as a single joint parameter, the upper two quartiles of adiponectin were associated with a modest reduction in breast cancer
risk (HRq4+q3-q1 = 0.76, 95% CI = 0.57 to 1.02, Ptrend = .06). However,
the association between adiponectin and breast cancer risk was
weakened following inclusion of insulin in the multivariable
model (HRq4+q3-q1 = 0.81, 95% CI = 0.59 to 1.12, Ptrend = .222, data
not shown). Levels of CRP and PAI-1 were positively associated
with breast cancer risk, but the associations differed by HT use
(see below). We detected no significant heterogeneity in any of
the results when stratified by BMI at baseline. The associations
of the adipokines and inflammatory markers with breast cancer
risk did not differ by breast tumor ER status.

CRP and PAI-1 Results Stratified by HT Use at
Baseline
The association of CRP level with breast cancer risk differed
according to HT use at baseline (Pinteraction = .003), and mean CRP
levels varied statistically significantly between HT nonusers (1.48
ug/mL) and HT users (2.65 ug/mL for estrogen-alone and 2.23 ug/
mL for estrogen plus progestin; P ≤ .001). Among women using
HT at baseline, CRP levels were unrelated to breast cancer risk
(HRq4-q1 = 0.90, 95% CI = 0.53 to 1.53, Ptrend = .509), while in nonHT users, CRP levels were positively associated with breast cancer incidence after controlling for established breast cancer risk
factors (Table 3). Specifically, compared with women in the lowest quartile of CRP, those in the third quartile had a statistically
significantly increased incidence of breast cancer (HRq3-q1 = 2.28,
95% CI = 1.36 to 3.81), while the hazard ratio for the highest quartile was of borderline statistical significance (HRq4-q1 = 1.63, 95%
CI = 0.95 to 2.80, Ptrend = .010) (Table 3). However, when combined,
the upper two quartiles of CRP were positively and significantly
associated with breast cancer risk (HRq4+q3-q1 = 1.98, 95% CI = 1.25 to
3.13, Ptrend = .003). Given that CRP can be a marker of acute inflammation, we further excluded participants with CRPs 10 µg/mL or
higher (considered evidence for acute infection) and observed no
change in the risk estimates (HRq4+q3-q1 = 1.85, 95% CI = 1.13 to 3.05,
Ptrend= .014). High CRP levels remained statistically significantly
associated with breast cancer risk in non-HT users even when
insulin was added into the multivariable model (HRq4+q3-q1 = 1.67,
95% CI = 1.04 to 2.68, Ptrend = .029) (Table 4). In addition, we restricted
our analysis to women who reported that they had never used
HT (71.4% of HT nonusers at baseline) and found the association of CRP with breast cancer risk to be essentially unaltered
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Table 1. Distribution of selected baseline characteristics among the breast cancer case patients and subcohort members without breast cancer*

Median age, y (IQR)
Race/ethnicity, No. (%)
White
Black
Hispanic
Asian/other
Highest education level, No. (%)
High school or less
Some college
College and above
  Missing
Age at menarche in y, No. (%)
≤11
12–13
≥14
  Missing
Age at menopause in y, No. (%)
≤42
43–48
49–51
≥52
  Missing
Years of menstrual cycling, No. (%)
≤33
34–38
≥39
  Missing
Parity, No. (%)
No live births
1
2–3
≥4
  Missing
Age at first child’s birth in y, No. (%)
≤19
20–24
25–29
≥30
  Missing
Ever use of oral contraceptives, No. (%)
Hormone therapy at baseline, No. (%)
Not using hormone therapy
Combined estrogen + progestin therapy
Unopposed estrogen therapy
  Missing
Smoking status, No. (%)
Never
Former
Current
  Missing
Median alcohol consumption, servings per week (IQR)
NSAID use ≥ 2 wks, No. (%)
Median body mass index, kg/m2 (IQR)
Median physical activity, METs/ wk (IQR)
First-degree relative with breast cancer, No. (%)
History of benign breast disease, No. (%)
Estrogen receptor status, No. (%)
Positive
Negative
  Missing

Case patients
(n = 875)

Subcohort members
(n = 821)†

P‡

64.0 (59.0–69.0)

63.0 (57.0–69.0)

.001

766 (87.5)
58 (6.6)
25 (2.9)
26 (3.0)

701 (85.4)
55 (6.7)
32 (3.9)
33 (4.0)

.402

152 (17.4)
304 (34.7)
409 (46.7)
10 (1.1)

167 (20.3)
303 (36.9)
342 (41.7)
9 (1.1)

.082

216 (24.7)
449 (51.3)
205 (23.4)
5 (0.6)

185 (22.5)
444 (54.1)
189 (23.0)
3 (0.4)

.479

127 (14.5)
189 (21.6)
219 (25.0)
260 (29.7)
80 (9.1)

180 (21.9)
195 (23.8)
182 (22.2)
199 (24.2)
65 (7.9)

< .001

237 (27.1)
267 (30.5)
289 (33.0)
82 (9.37)

287 (35.0)
252 (30.7)
216 (26.3)
66 (8.0)

.001

120 (13.7)
63 (7.2)
446 (51.0)
241 (27.5)
5 (0.6)

120 (14.6)
72 (8.8)
402 (49.0)
222 (27.0)
5 (0.6)

.586

83 (11.0)
288 (38.2)
234 (31.0)
79 (10.5)
71 (9.4)
356 (40.7)

78 (11.1)
320 (45.7)
170 (24.3)
58 (8.3)
75 (10.7)
337 (41.1)

.002

412 (47.1)
239 (27.3)
224 (25.6)
0

447 (54.4)
182 (22.2)
191 (23.3)
1 (0.1)

.007

419 (47.9)
404 (46.2)
39 (4.5)
13 (1.5)
0.6 (0.0–3.8)
371 (42.4)
25.9 (23.2–30.3)
10.5 (3.4–19.8)
217 (24.8)
329 (37.6)

439 (53.5)
320 (39.0)
52 (6.3)
10 (1.2)
0.4 (0.0–2.7)
298 (36.3)
26.2 (23.3–29.7)
10.0 (3.8–20.0)
150 (18.3)
259 (31.6)

.005

554 (63.3)
253 (28.9)
68 (7.8)

----

.880

.006
.010
.894
.784
.005
.009
--
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Table 1. Continued
Case patients
(n = 875)

Subcohort members
(n = 821)†

P‡

13950 (7433–25025)
28597 (20109–40085)
12.1 (9.7–15.1)
2.3 (1.0–4.7)
1.4 (0.9–2.3)
2.5 (1.8–3.4)
14237 (9300–21076)
611 (401–873)
5.7 (3.5–8.8)
11.9 (8.0–16.0)

14406 (6974–24698)
29317 (20498–39929)
12.3 (9.8–15.6)
1.9 (0.9–4.4)
1.4 (0.9–2.2)
2.6 (1.8–3.6)
14076 (8898–20726)
604 (404–855)
5.3 (3.3–8.5)
11.0 (7.0–16.0)

.497
.571
.454
.057
.794
.756
.409
.588
.196
.025

Variable
Median levels of analytes (IQR)
Leptin, pg/mL
Adiponectin, ng/mL
Resistin, ng/mL
CRP, μg/mL
IL-6, pg/mL
TNF-α, pg/mL
PAI-1, pg/mL
HGF, pg/mL
Insulin, µIU/mL
Estradiol, pg/mL§

* All statistical tests were two-sided. IQR = interquartile range; METs = metabolic equivalent tasks (defined as the caloric need per kilogram of body weight per hour
of activity divided by the caloric need per kilogram of body weight per hour at rest); NSAID = nonsteroidal anti-inflammatory drug.
† Excludes women who developed breast cancer during follow-up.
‡ Missing are excluded for P value calculation.
§ Among women not using hormone therapy at baseline.

(HRq4+q3-q1 = 1.77, 95% CI = 0.95 to 3.29), albeit the association was
of borderline significance because of the reduced sample size.
We also investigated whether the association of CRP with breast
cancer risk differed by tumor ER status in HT nonusers separately.
Among HT nonusers, and in a multivariable model that included
insulin, estradiol, BMI, and other breast cancer risk factors, the
association between CRP and breast cancer incidence was not
substantially different for ER+ (HRq4+q3-q1 = 1.68, 95% CI = 0.97 to
2.89) and ER- tumors (HRq4+q3-q1 = 2.10, 95% CI = 1.04 to 4.23).
We also observed heterogeneity in the association of
PAI-1 with breast cancer by HT use such that among non-HT
users, PAI-1 levels were positively associated with breast cancer risk (HRq4-q1 = 1.71, 95% CI = 1.02 to 2.89, Ptrend = .077), while
among HT-users there was no association with breast cancer
(HRq4-q1 = 1.17, 95% CI = 0.17 to 1.93, Ptrend = .663); however, the
formal test of interaction was not significant (P = .238). Further,
including insulin in the multivariable model attenuated the positive association between PAI-1 and breast cancer among nonHT users (HRq4-q1 = 1.49, 95% CI = 0.85 to 2.61, Ptrend = .270).
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Mediation of the Obesity–Breast Cancer Association
by Estradiol, Insulin, and CRP
As shown in Table 4, among non-HT users, insulin, estradiol, and
CRP were each positively and statistically significantly associated with breast cancer, even after mutual adjustment for one
another. We next evaluated whether the obesity-related factors
that were statistically significantly associated with breast cancer risk could provide a mechanistic link between obesity and
breast cancer. We examined, among non-HT users, whether
the strength of association between obesity and breast cancer
risk would change after accounting for the potential mediating effects of estradiol, insulin, and/or CRP. Table 5 shows that
a BMI of 30 kg/m2 or more, compared with a BMI under 25 kg/
m2, was statistically significantly associated with an increased
breast cancer risk (HR = 1.87, 95% CI = 1.25 to 2.80, Ptrend = .003)
while controlling for other breast cancer risk factors, except
estradiol, insulin, and CRP. When estradiol was added into the
model, the obesity association with breast cancer was weakened,
but remained statistically significant (HR = 1.69, 95% CI = 1.11 to
2.59, Ptrend = .018). However, following inclusion of insulin or CRP
in the model, the hazard ratio for BMI of 30 or more vs under

25 kg/m2 was attenuated and no longer significant. The hazard
ratio for BMI of 30 kg/m2 or more vs under 25 kg/m2 was reduced
to 0.91 (95% CI = 0.52 to 1.61, Ptrend = .780) when all three obesity-related factors were entered into the model simultaneously.
Figure 1 shows that the β-coefficient for BMI of 30 kg/m2 or more
decreased 16%, 52%, 53%, 92%, and 115% following adjustment for
estradiol, insulin, CRP, both insulin and CRP, or all three factors
simultaneously, respectively. On the other hand, the associations
of CRP, insulin, and estradiol each remained statistically significantly associated with breast cancer after mutual adjustment for
one another (Table 4). The association of BMI with breast cancer
did not materially change when we excluded women with a BMI
under 18.5 kg/m2 or when BMI was modeled as a continuous variable (data not shown). Finally, the degree of attenuation of the
BMI–breast cancer association by insulin, estradiol, and CRP did
not differ depending on ER status of the breast tumor: for ER+,
the hazard ratio comparing a BMI of more than 30 kg/m2 with
BMI between 18.5 and 25.0 kg/m2 was 1.80 (95% CI = 1.12 to 2.88);
for inclusion of insulin, estradiol, and CRP, the hazard ratio comparing BMI of more than 30 kg/m2 with BMI between 18.5 and
25.0 kg/m2 was 0.82 (95% CI = 0.43 to 1.57); for ER-, the hazard
ratio comparing BMI of more than 30 kg/m2 with BMI between
18.5 and 25.0 kg/m2 was 1.80 (95% CI = 1.02 to 3.16); for inclusion
of insulin, estradiol, and CRP, the hazard ratio comparing BMI of
more than 30 kg/m2 with BMI between 18.5 and 25.0 kg/m2 was
0.95 (95% CI = 0.41 to 2.19).

Discussion
In this prospective investigation of postmenopausal women,
higher circulating CRP levels were associated with increased incidence of breast cancer among women not using HT. Specifically,
the breast cancer incidence rate in these women was two-fold
greater among those in the highest two quartiles compared with
those in the lowest quartile of CRP, even after controlling for
estradiol, insulin, BMI, and established breast cancer risk factors.
CRP is an acute phase, liver-derived peptide that is routinely
measured clinically as a nonspecific inflammatory marker.
Circulating levels of CRP have been shown to be predictive of risk
of cardiovascular disease (34) and type II diabetes (35), and CRP
levels have also been associated with colorectal cancer risk (36).
However, epidemiologic data relating circulating CRP concentrations to breast cancer are more limited and the majority of
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Factor, model
Leptin
Quartile cutpoints, pg/mL
No. case patients/No. subcohort members
Age and ethnicity adjusted HR (95% CI)
Multivariable-adjusted HR* (95% CI)
Adiponectin
Quartile cutpoints, ng/mL
No. case patients/No. subcohort members
Age and ethnicity adjusted HR (95% CI)
Multivariable-adjusted HR* (95% CI)
Resistin
Quartile cutpoints, ng/mL
No. case patients/No. subcohort members
Age and ethnicity adjusted HR (95% CI)
Multivariable-adjusted HR* (95% CI)
CRP
Quartile cutpoints, µg/mL
No. case patients/No. subcohort members
Age and ethnicity adjusted HR (95% CI)
Multivariable-adjusted HR* (95% CI)
IL-6
Quartile cutpoints, pg/mL
No. case patients/No. subcohort members
Age and ethnicity adjusted HR (95% CI)
Multivariable-adjusted HR* (95% CI)
TNF-α
Quartile cutpoints, pg/mL
No. case patients/No. subcohort members
Age and ethnicity adjusted HR (95% CI)
Multivariable-adjusted HR* (95% CI)
PAI-1
Quartile cutpoints, pg/mL
No. case patients/No. subcohort members
Age and ethnicity adjusted HR (95% CI)
Multivariable-adjusted HR* (95% CI)
HGF
Quartile cutpoints, pg/mL
No. case patients/No. subcohort members
Age and ethnicity adjusted HR (95% CI)
Multivariable-adjusted HR* (95% CI)

Quartile 1

Quartile 2

Quartile 3

Quartile 4

Ptrend

≤7294
211/216
1.00 (referent)
1.00 (referent)

7295-15 007
260/208
1.26 (0.96 to 1.65)
1.56 (1.13 to 2.15)

15 008–25 517
190/204
0.97 (0.73 to 1.28)
1.14 (0.79 to 1.65)

≥25 518
213/193
1.20 (0.91 to 1.59)
1.39 (0.93 to 2.09)

.554
.279

≤19 678
210/183
1.00 (referent)
1.00 (referent)

19 679–28 326
223/206
0.92 (0.69 to 1.22)
0.88 (0.65 to 1.20)

28 327–39 526
220/213
0.88 (0.66 to 1.17)
0.76 (0.55 to 1.06)

≥39 527
222/218
0.84 (0.63 to 1.11)
0.76 (0.55 to 1.06)

.212
.078

≤9.86
229/212
1.00 (referent)
1.00 (referent)

9.87–12.46
234/209
1.03 (0.79 to 1.35)
1.01 (0.75 to 1.37)

12.47–15.70
221/200
0.96 (0.73 to 1.26)
0.99 (0.73 to 1.35)

≥15.8
191/200
0.85 (0.64 to 1.13)
0.93 (0.68 to 1.27)

.227
.664

≤0.91
199/208
1.00 (referent)
1.00 (referent)

0.92–2.01
195/207
0.99 (0.75 to 1.31)
1.01 (0.73 to 1.39)

2.02–4.57
238/195
1.34 (1.02 to 1.77)
1.31 (0.93 to 1.85)

≥4.58
223/188
1.32 (1.00 to 1.75)
1.24 (0.86 to 1.80)

.012
.120

≤0.92
226/206
1.00 (referent)
1.00 (referent)

0.93–1.47
230/209
0.92 (0.70 to 1.21)
1.03 (0.75 to 1.42)

1.48–2.31
187/202
0.82 (0.62 to 1.09)
0.87 (0.63 to 1.22)

≥2.32
213/178
1.08 (0.82 to 1.43)
1.20 (0.85 to 1.69)

.801
.528

≤1.81
220/204
1.00 (referent)
1.00 (referent)

1.82–2.62
235/204
1.03 (0.78 to 1.35)
1.01 (0.75 to 1.37)

2.63–3.62
222/203
0.97 (0.73 to 1.27)
1.00 (0.74 to 1.36)

≥3.63
179/188
0.80 (0.60 to 1.08)
0.82 (0.59 to 1.14)

.144
.292

≤9187
207/210
1.00 (referent)
1.00 (referent)

9188-14 395
231/204
1.20 (0.92 to 1.58)
1.29 (0.95 to 1.74)

14 396–21 348
212/198
1.09 (0.83 to 1.44)
1.18 (0.86 to 1.63)

≥21 349
208/187
1.14 (0.86 to 1.50)
1.33 (0.96 to 1.86)

.513
.145

≤407
223/209
1.00 (referent)
1.00 (referent)

408–613
217/212
0.93 (0.70 to 1.22)
1.03 (0.76 to 1.39)

614–869
214/210
0.93 (0.71 to 1.22)
0.97 (0.71 to 1.31)

≥870
220/189
1.03 (0.78 to 1.36)
1.20 (0.87 to 1.65)

.867
.369

*Multivariable model adjusted for age, ethnicity, alcohol consumption, family history of breast cancer, parity, years of menstrual cycling, age at first child’s birth,
use of hormone therapy, endogenous estradiol levels (in non–hormone therapy users only), history of benign breast disease, body mass index, and physical activity.
All statistical tests were two-sided. CI = confidence interval; CRP = C-reactive protein; HGF = hepatocyte growth factor; HR = hazard ratio; IL-6 = interleukin-6; PAI1 = plasminogen activator inhibitor–1; TNF-α = tumor necrosis factor-α; WHI-OS = Women’s Health Initiative Observational Study.

prospective studies have reported null findings (16,18). However,
a nested case-control study conducted in the Multiethnic Cohort
that included 706 postmenopausal breast cancer case patients
and 706 matched control patients reported a positive, albeit
nonlinear, association between circulating CRP and breast cancer risk, even after adjustment for BMI and other breast cancer
risk factors (37). More recently, a prospective analysis in the E3N
cohort in France did not report a statistically significant association between CRP levels and breast cancer risk overall, though
there was evidence for a statistical interaction with BMI, such
that higher CRP levels were positively associated with breast
cancer incidence among overweight and obese women (21). In
the current study, there was no evidence of heterogeneity in the
association of CRP levels with breast cancer by BMI, though we
found a positive CRP association among non-HT users but not in
HT users. It is difficult to discern the discrepancies between the

E3N and WHI results, particularly when data stratified by HT use
were not available in the E3N study. If women who were overweight or obese tended not to use HT after menopause, as was
the case in the WHI postmenopausal women, then the interaction between CRP and BMI observed in the E3N study could be
explained by HT use. In our study, the relationship between CRP
and breast cancer persisted even after simultaneous adjustment
for BMI, estradiol, and insulin levels. This finding suggests that
CRP may represent an inflammatory mechanism or a closely
linked pathway that is associated with breast cancer development that is independent of hyperinsulinemia and estrogen.
A possible explanation for why CRP levels were not associated with breast cancer in HT users is that HT use is a major risk
factor for breast cancer and further exposure to inflammation in
the presence of HT may be relatively unimportant. In addition,
the hepatic first-pass effect of HT can artificially raise the levels

article

Table 2. Adjusted hazard ratios (and 95% CIs) for associations of incident breast cancer with baseline levels of adipokines and inflammatory
markers in the WHI-OS participants
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Table 3. Adjusted hazard ratios (and 95% CIs) for associations of incident breast cancer with baseline levels of CRP and PAI-1 with stratification
by HT use
Factor, model
Non-HT users at baseline
CRP
Quartile cutpoints, µg/mL
No. case patients/No. subcohort members
Age and ethnicity adjusted HR (95% CI)
Multivariable-adjusted HR* (95% CI)
PAI-1
Quartile cutpoints, pg/mL
No. case subjects/No. subcohort members
Age and ethnicity adjusted HR (95% CI)
Multivariable-adjusted HR* (95% CI)
HT users at baseline
CRP
Quartile cutpoints, µg/mL
No. case patients/No. subcohort members
Age- and ethnicity-adjusted HR (95% CI)
Multivariable-adjusted HR* (95% CI)
PAI-1
Quartile cutpoints, pg/mL
No. case patients/No. subcohort members
Age- and ethnicity-adjusted HR (95% CI)
Multivariable-adjusted HR* (95% CI)

Quartile 1

Quartile 2

Quartile 3

Quartile 4

Ptrend

≤0.91
113/149
1.00 (referent)
1.00 (referent)

0.92–2.01
97/122
1.02 (0.71 to 1.48)
1.00 (0.65 to 1.56)

2.02–4.57
110/84
1.82 (1.23 to 2.68)
2.28 (1.36 to 3.81)

≥4.58
81/79
1.40 (0.93 to 2.10)
1.63 (0.95 to 2.80)

.010
.010

≤9187
55/79
1.00 (referent)
1.00 (referent)

9188-14 395
96/102
1.38 (0.88 to 2.15)
1.47 (0.88 to 2.46)

14 396–21 348
114/125
1.35 (0.88 to 2.09)
1.49 (0.89 to 2.52)

≥21 349
138/129
1.62 (1.06 to 2.48)
1.71 (1.02 to 2.89)

.045
.077

≤0.91
86/59
1.00 (referent)
1.00 (referent)

0.92–2.01
98/85
0.82 (0.52 to 1.28)
0.96 (0.56 to 1.66)

2.02–4.57
128/111
0.80 (0.52 to 1.22)
0.75 (0.45 to 1.24)

≥4.58
142/108
0.94 (0.62 to 1.45)
0.90 (0.53 to 1.53)

.918
.509

≤9187
152/131
1.00 (referent)
1.00 (referent)

9188-14 395
135/101
1.26 (0.87 to 1.81)
1.31 (0.86 to 1.97)

14 396–21 348
98/73
1.18 (0.80 to 1.75)
1.06 (0.65 to 1.72)

≥21 349
70/58
1.04 (0.68 to 1.59)
1.17 (0.71 to 1.93)

.706
.663

* Multivariable model adjusted for age, ethnicity, alcohol consumption, family history of breast cancer, parity, years of menstrual cycling, age at first child’s birth, type
of hormone therapy (HT; in HT users only), endogenous estradiol levels (in non-HT users only), history of benign breast disease, body mass index, and physical activity. All statistical tests were two-sided. CI = confidence interval; CRP = C-reactive protein; HR = hazard ratio; HT = hormone therapy; PAI-1 = plasminogen activator
inhibitor–1.

Table 4. Multivariable hazard ratios (and 95% CIs) for the associations of obesity-related factors with breast cancer risk among nonHT users at baseline
Covariates*

article

Estradiol, pg/mL
<8
≥8
Insulin, μIU/mL
≤3.3
3.4–5.3
5.4–8.5
≥8.6
CRP, μg/mL
≤0.91
0.92–2.01
≥2.02

HR (95% CI)

Ptrend

1.00 (referent)
1.52 (1.02 to 2.26)

.040

1.00 (referent)
1.20 (0.69 to 2.07)
1.60 (0.93 to 2.73)
2.37 (1.30 to 4.30)

.003

1.00 (referent)
0.98 (0.63 to 1.54)
1.67 (1.04 to 2.68)

.029

*Multivariable model included estradiol, insulin, C-reactive protein, and the following covariates: age, race/ethnicity, body mass index, alcohol consumption,
family history of breast cancer, parity, years of menstrual cycling, age at first
child’s birth, history of benign breast disease, and physical activity. All statistical tests were two-sided. CI = confidence interval; CRP = C-reactive protein;
HR = hazard ratio; HT = hormone therapy.

of circulating CRP such that a relatively high CRP level may not
necessarily reflect a proinflammatory status in HT users (32).
Indeed, in the current analysis, CRP levels were statistically significantly raised among HT users with the highest geometric
mean levels observed in estrogen-alone users, intermediate in
estrogen-plus-progestin users, and lowest in HT nonusers.
In this study, we found null to modest associations between
breast cancer risk and circulating levels of adipokines, despite
the fact that they can have significant biological impact on

insulin sensitivity, inflammatory response, cell proliferation
and apoptosis, and estrogen metabolism—all processes that
have been implicated in breast cancer tumorigenesis (38–40).
Adiponectin, an adipokine that is downregulated in obesity and
has insulin-sensitizing properties and antiproliferative effects
on breast epithelial cells, tended to be inversely associated with
breast cancer risk in our analysis—a finding that is consistent
with prior data (8,12–14). However, following inclusion of insulin in the multivariable model this association was attenuated
and became null, suggesting that the effects of adiponectin on
breast cancer risk are partly explained by insulin. Similarly, PAI1, an adipokine that is upregulated in obesity, was positively
associated with breast cancer risk in non-HT users; however,
this association was attenuated and lost statistical significance
following adjustment for insulin. We previously reported a positive and robust association between insulin levels and postmenopausal breast cancer risk in the same participants of the
WHI-OS who were tested as part of the current investigation (3).
In that analysis, women in the highest quartile of insulin were
at a greater-than-two-fold higher risk of developing breast cancer than those in the lowest quartile, and this association was
independent of BMI and endogenous estradiol levels. Given that
both adiponectin and PAI-1 have effects on insulin sensitivity
and that hyperinsulinemia is a statistically significant positive
risk factor for breast cancer, it may be inferred that any effects
of these adipokines on breast cancer risk may be mediated
through insulin.
One of the advantages of our case-cohort study was that we
had measurements on various obesity-related factors and were
able to evaluate whether those statistically significantly associated with breast cancer risk, namely insulin, estradiol, and
CRP, could be intervening variables linking obesity with development of breast cancer. Our data showed that the relation of
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Table 5. Multivariable hazard ratios (and 95% CIs) for the association of incident breast cancer and BMI among non-HT users at baseline
Factor, model
BMI
Category cutpoints, kg/m2
No. case patients /No. subcohort members
Base model*
Base + estradiol
Base + insulin
Base + CRP
Base + insulin + CRP
Base + estradiol + insulin + CRP

Quantile 1

Quantile 2

Quantile 3

Ptrend

≤24.9
135/162
1.00 (referent)
1.00 (referent)
1.00 (referent)
1.00 (referent)
1.00 (referent)
1.00 (referent)

25.0–29.9
135/155
1.17 (0.81 to 1.69)
1.13 (0.77 to 1.64)
0.89 (0.59 to 1.34)
1.01 (0.67 to 1.52)
0.79 (0.51 to 1.23)
0.74 (0.47 to 1.17)

≥30.0
137/116
1.87 (1.25 to 2.80)
1.69 (1.11 to 2.59)
1.35 (0.85 to 2.17)
1.34 (0.82 to 2.18)
1.05 (0.61 to 1.81)
0.91 (0.52 to 1.61)

.003
.018
.201
.251
.823
.780

*Base model adjusted for age, race/ethnicity, alcohol consumption, family history of breast cancer, parity, years of menstrual cycling, age at first child’s birth, history of benign breast disease, and physical activity. All statistical tests were two-sided. BMI = body mass index; CI = confidence interval; CRP = C-reactive protein;
HT = hormone therapy.

obesity with breast cancer risk was entirely attenuated after
adjustment for endogenous estradiol, insulin, and CRP, with the
latter two being the major factors contributing to the attenuation of the obesity–breast cancer association. Our observations
are consistent with the hypothesis that obesity-induced hyperinsulinemia and chronic inflammation are part of the biological mechanisms leading to breast cancer. Given that CRP is a
nonspecific inflammatory marker, our findings raise questions
regarding the precise mechanism by which inflammation could
be related to breast cancer development. A potential limitation
in the evaluation of adipokines in relation to breast cancer is
that adipokines primarily function in a paracrine manner and
the measurement of circulating levels may not accurately reflect
processes at the tissue level. It is not known to what extent circulating levels of cytokines are associated with levels in breast
or adipose tissue, and it is possible that plasma levels may be a
poor surrogate for local levels, at least for some of the cytokines.
In conclusion, our data indicate that relatively high levels
of CRP are positively associated with risk of postmenopausal
breast cancer in women not using HT, and this relationship is
largely independent of other obesity-related pathways such
as hyperinsulinemia and estrogen. Further, CRP, insulin, and
estradiol together appear to explain all of the association of

BMI with breast cancer development. Interventions aimed at
lowering CRP levels, alongside insulin and estrogen, may be
effective at reducing risk of breast cancer in postmenopausal
women.
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Figure 1. Beta coefficients for the association between body mass index ≥ 30 kg/m2 and breast cancer after accounting for possible mediation by estradiol, insulin, and/
or C-reactive protein (CRP) among non-HT users at baseline. Vertical lines represent the 95% confidence intervals. Base model adjusted for age, race/ethnicity, alcohol
consumption, family history of breast cancer, parity, years of menstrual cycling, age at first child’s birth, history of benign breast disease, and physical activity.
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